Suchergebnisse - "Recombinant Fusion Proteins therapeutic use"
-
1
Autoren: et al.
Quelle: Eye (Lond)
Eye, vol. 39, no. 11, pp. 2188-2193Schlagwörter: Humans, Retrospective Studies, Aged, Visual Acuity/physiology, Angiogenesis Inhibitors/therapeutic use, Angiogenesis Inhibitors/administration & dosage, Male, Female, Receptors, Vascular Endothelial Growth Factor/administration & dosage, Receptors, Vascular Endothelial Growth Factor/therapeutic use, Recombinant Fusion Proteins/therapeutic use, Recombinant Fusion Proteins/administration & dosage, Intravitreal Injections, Ranibizumab/administration & dosage, Ranibizumab/therapeutic use, Aged, 80 and over, Wet Macular Degeneration/drug therapy, Wet Macular Degeneration/physiopathology, Wet Macular Degeneration/diagnosis, Vascular Endothelial Growth Factor A/antagonists & inhibitors, Follow-Up Studies, Treatment Outcome, Tomography, Optical Coherence, Article
Dateibeschreibung: application/pdf
-
2
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Acta cardiologica, Vol. 79, no. 9, p. 978-983 (2024)
Acta cardiologicaSchlagwörter: Consensus, Recombinant Fusion Proteins, Hypertension, Pulmonary, Activin Receptors, Type II, Systèmes cardiovasculaire & respiratoire, Sciences de la santé humaine, Hypertension, Pulmonary/drug therapy, Belgium, pulmonary arterial hypertension, pulmonary artery, pulmonary hypertension, Cardiovascular & respiratory systems, Humans, Human health sciences, Pulmonary Arterial Hypertension, Sciences bio-médicales et agricoles, vascular remodelling, Recombinant Fusion Proteins/therapeutic use, Treatment Outcome, Activin Receptors, Type II/therapeutic use, Human medicine, Sotatercept, Cardiology and Cardiovascular Medicine, Pulmonary Arterial Hypertension/drug therapy
Dateibeschreibung: 1 full-text file(s): application/vnd.openxmlformats-officedocument.wordprocessingml.document
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39377139
https://hdl.handle.net/2268/325198
https://doi.org/10.1080/00015385.2024.2408130
https://hdl.handle.net/2078.1/293774
https://hdl.handle.net/10067/2095110151162165141
https://repository.uantwerpen.be/docstore/d:irua:26251
https://biblio.vub.ac.be/vubir/a-belgian-consensus-on-sotatercept-for-the-treatment-of-pulmonary-arterial-hypertension(bd47be31-c13c-45bf-a07b-d63c96a07b2e).html -
3
Autoren: et al.
Quelle: Christiansen, C F, Risbo, N, Ghanima, W, Linder, M, Bahmanyar, S, Seesaghur, A, Clouser, M, Nørgaard, M & Sørensen, H T 2024, 'Platelet response to romiplostim amongst patients with newly diagnosed, persistent, and chronic immune thrombocytopenia in routine clinical practice in Denmark, Sweden, and Norway', British Journal of Haematology, vol. 205, no. 4, pp. 1497-1507. https://doi.org/10.1111/bjh.19688
Schlagwörter: Male, Adult, Blood Platelets, Recombinant Fusion Proteins, Denmark, immune thrombocytopenia (ITP), effectiveness, thrombocytopenia, Receptors, Fc, Receptors, Fc/therapeutic use, 03 medical and health sciences, 0302 clinical medicine, Humans, Purpura, Thrombocytopenic, Idiopathic/drug therapy, Aged, Sweden, Aged, 80 and over, Purpura, Thrombocytopenic, Idiopathic, Norway, Platelet Count, romiplostim, Middle Aged, Norway/epidemiology, Recombinant Fusion Proteins/therapeutic use, Denmark/epidemiology, Thrombopoietin/therapeutic use, Sweden/epidemiology, Treatment Outcome, Thrombopoietin, platelets, Chronic Disease, Blood Platelets/drug effects, Female
Dateibeschreibung: application/pdf
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39102877
https://pure.au.dk/portal/en/publications/fd96cda4-3109-47a8-b3c2-591855adb103
https://pure.au.dk/portal/en/publications/fd96cda4-3109-47a8-b3c2-591855adb103
https://pure.au.dk/ws/files/433071078/Br_J_Haematol_-_2024_-_Christiansen_-_Platelet_response_to_romiplostim_amongst_patients_with_newly_diagnosed_persistent_.pdf
http://www.scopus.com/inward/record.url?scp=85200330072&partnerID=8YFLogxK
https://doi.org/10.1111/bjh.19688 -
4
Autoren: et al.
Quelle: Die Ophthalmologie, 121(8):650-657
Schlagwörter: Intravitreal aflibercept, Aged [MeSH], Retinal vein occlusion, Real-World, Tomography, Optical Coherence [MeSH], Receptors, Vascular Endothelial Growth Factor/administration, Treatment naïve, Macular Edema/drug therapy [MeSH], Makulaödem, Originalien, Male [MeSH], Real world, Behandlungsnaiv, Visual Acuity/drug effects [MeSH], Receptors, Vascular Endothelial Growth Factor/therapeutic use [MeSH], Recombinant Fusion Proteins/therapeutic use [MeSH], Female [MeSH], Follow-Up Studies [MeSH], Macular edema, Intravitreal Injections [MeSH], Angiogenesis Inhibitors/administration, Humans [MeSH], Prospective Studies [MeSH], Treatment Outcome [MeSH], Middle Aged [MeSH], Retinal Vein Occlusion/complications [MeSH], Retinaler Venenverschluss, Intravitreales Aflibercept, Germany [MeSH], Angiogenesis Inhibitors/adverse effects [MeSH], Retinal Vein Occlusion/drug therapy [MeSH], Recombinant Fusion Proteins/adverse effects [MeSH], Angiogenesis Inhibitors/therapeutic use [MeSH], Recombinant Fusion Proteins/administration, 3. Good health
Zugangs-URL: https://repository.publisso.de/resource/frl:6519973
-
5
Autoren: et al.
Quelle: Adv Ther
Schlagwörter: Macular Degeneration, Receptors, Vascular Endothelial Growth Factor, Treatment Outcome, Anatomic outcomes, Anti-vascular endothelial growth factor, Fixed dosing, Functional outcomes, Intravitreal aflibercept, Neovascular age-related macular degeneration, Treat-and-extend, Treatment burden, Treatment interval, Recombinant Fusion Proteins, Intravitreal Injections, Visual Acuity, Humans, Macular Degeneration/drug therapy [MeSH], Intravitreal Injections [MeSH], Aged [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Middle Aged [MeSH], Visual Acuity [MeSH], Original Research, Receptors, Vascular Endothelial Growth Factor/therapeutic use [MeSH], Recombinant Fusion Proteins/therapeutic use [MeSH], Middle Aged, Aged
Dateibeschreibung: application/pdf
-
6
Autoren: et al.
Quelle: Eye (Lond)
Schlagwörter: Male, Aged, 80 and over, Vascular Endothelial Growth Factor A, Recombinant Fusion Proteins, Subretinal Fluid, Visual Acuity, Angiogenesis Inhibitors, Middle Aged, Aged, 80 and over [MeSH], Aged [MeSH], Tomography, Optical Coherence [MeSH], 692/53/2423, Receptors, Vascular Endothelial Growth Factor/administration, Male [MeSH], Visual Acuity/physiology [MeSH], Wet Macular Degeneration/diagnosis [MeSH], Receptors, Vascular Endothelial Growth Factor/therapeutic use [MeSH], Recombinant Fusion Proteins/therapeutic use [MeSH], Female [MeSH], Wet Macular Degeneration/drug therapy [MeSH], Intravitreal Injections [MeSH], Angiogenesis Inhibitors/administration, Humans [MeSH], Vascular Endothelial Growth Factor A/antagonists, Wet Macular Degeneration/physiopathology [MeSH], Middle Aged [MeSH], 706/703, Article, Subretinal Fluid [MeSH], ROC Curve [MeSH], Angiogenesis Inhibitors/therapeutic use [MeSH], article, Recombinant Fusion Proteins/administration, Receptors, Vascular Endothelial Growth Factor, ROC Curve, Intravitreal Injections, Wet Macular Degeneration, Humans, Female, Tomography, Optical Coherence, Aged
-
7
Autoren: et al.
Quelle: J Cancer Res Clin Oncol
Schlagwörter: 03 medical and health sciences, 0302 clinical medicine, Tagraxofusp, MDS, Hematologic Neoplasms/genetics [MeSH], Aged [MeSH], Skin Neoplasms/drug therapy [MeSH], Letter to the Editor, Diagnosis, Differential [MeSH], Male [MeSH], Blast Crisis/drug therapy [MeSH], Hematologic Neoplasms/diagnosis [MeSH], Skin Neoplasms/metabolism [MeSH], Myeloid neoplasia, Diagnostic Errors/prevention, Recombinant Fusion Proteins/therapeutic use [MeSH], Dendritic Cells/pathology [MeSH], Mutation [MeSH], Humans [MeSH], Hematologic Neoplasms/drug therapy [MeSH], Blastic plasmacytoid dendritic cell-neoplasms (BPDCN), Dendritic Cells/drug effects [MeSH], Skin Neoplasms/genetics [MeSH], Blast Crisis/metabolism [MeSH], Biomarkers, Tumor/genetics [MeSH], Prognosis [MeSH], Hematologic Neoplasms/metabolism [MeSH], Skin Neoplasms/diagnosis [MeSH], Blast Crisis/pathology [MeSH], Dendritic Cells/metabolism [MeSH], Antigens, CD/metabolism [MeSH], Blast Crisis/genetics [MeSH], AML, 3. Good health
Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00432-021-03777-2.pdf
http://www.ncbi.nlm.nih.gov/pubmed/34529129
https://link.springer.com/content/pdf/10.1007/s00432-021-03777-2.pdf
https://pubmed.ncbi.nlm.nih.gov/34529129/
https://link.springer.com/article/10.1007/s00432-021-03777-2
https://repository.publisso.de/resource/frl:6449816 -
8
Autoren:
Quelle: Graefes Arch Clin Exp Ophthalmol
Schlagwörter: Anti-VEGF therapy, Intravitreal Injections [MeSH], Retinal oxygen saturation, Humans [MeSH], Prospective Studies [MeSH], Oxygen Saturation [MeSH], Diabetic Retinopathy/drug therapy [MeSH], Retina [MeSH], Tomography, Optical Coherence [MeSH], Macular Edema/drug therapy [MeSH], Retinal Disorders, Diabetic macular edema, Macular Edema/diagnosis [MeSH], Aflibercept, Diabetes Mellitus [MeSH], Diabetic Retinopathy/complications [MeSH], Macular Edema/etiology [MeSH], Receptors, Vascular Endothelial Growth Factor/therapeutic use [MeSH], Angiogenesis Inhibitors/therapeutic use [MeSH], Diabetic retinopathy, Diabetic Retinopathy/diagnosis [MeSH], Recombinant Fusion Proteins/therapeutic use [MeSH], Diabetic Retinopathy, Recombinant Fusion Proteins, Angiogenesis Inhibitors, Macular Edema, Retina, 3. Good health, 03 medical and health sciences, Receptors, Vascular Endothelial Growth Factor, 0302 clinical medicine, Oxygen Saturation, Intravitreal Injections, Diabetes Mellitus, Humans, Prospective Studies, Tomography, Optical Coherence
Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00417-021-05319-5.pdf
https://pubmed.ncbi.nlm.nih.gov/34468834
https://link.springer.com/content/pdf/10.1007/s00417-021-05319-5.pdf
https://pubmed.ncbi.nlm.nih.gov/34468834/
http://www.ncbi.nlm.nih.gov/pubmed/34468834
https://link.springer.com/article/10.1007%2Fs00417-021-05319-5
https://repository.publisso.de/resource/frl:6450126 -
9
Autoren: et al.
Quelle: Eur J Paediatr Neurol
Schlagwörter: Consensus, Pédiatrie, Recombinant Fusion Proteins, Zolgensma, Muscular Atrophy, Spinal/genetics/therapy, Pediatrics, Sciences de la santé humaine, Article, Muscular Atrophy, Spinal, 03 medical and health sciences, Gene therapy, 0302 clinical medicine, Nusinersen, Neurologie, Onasemnogene abeparvovec, Humans, Genetic Therapy/methods, Human health sciences, Biological Products, Patient Selection, Infant, Genetic Therapy, Spinal muscular atrophy, Recombinant Fusion Proteins/therapeutic use, 3. Good health, Neurology, Biological Products/therapeutic use, SMN1, SMN2
-
10
Autoren: et al.
Quelle: Acta Ophthalmol
Jørgensen, M M, Vestergaard, A H, Blindbæk, S L, Peto, T & Grauslund, J 2022, 'Functional and structural efficacy of a novel combinational therapy of aflibercept and timely focal/grid photocoagulation in diabetic macular oedema: do clinical study results compare favourably with a standard-of-care treated real-world population?', Acta ophthalmologica. https://doi.org/10.1111/aos.15196
Jørgensen, M, Vestergaard, A H, Blindbæk, S L, Peto, T & Grauslund, J 2021, ' Functional and Structural Efficacy of a Novel Combinational Therapy of Aflibercept and Timely Focal/Grid Photocoagulation in Diabetic Macular Edema: Do Clinical Study Results Compare Favorably with a Standard-Of-Care Treated Real-Life Population? ', European Journal of Ophthalmology, vol. 31, no. 2 Suppl., pp. 40-41 . < https://journals.sagepub.com/doi/full/10.1177/11206721211047031 >Schlagwörter: Adult, Vascular Endothelial Growth Factor A, Recombinant Fusion Proteins, Angiogenesis Inhibitors, registry based, Ranibizumab/therapeutic use, Macular Edema, Diabetes Mellitus/drug therapy, Macular Edema/diagnosis, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Ranibizumab, Receptors, Diabetes Mellitus, Humans, name=SDG 3 - Good Health and Well-being, ranibizumab, Laser Coagulation/methods, Diabetic Retinopathy, Laser Coagulation, macular oedema, Vascular Endothelial Growth Factor, aflibercept, real world, diabetes complications, Original Articles, Recombinant Fusion Proteins/therapeutic use, diabetic retinopathy, Receptors, Vascular Endothelial Growth Factor, Intravitreal Injections, Diabetic Retinopathy/complications, Original Article
Dateibeschreibung: application/pdf
-
11
Autoren: et al.
Schlagwörter: Antibodies, Monoclonal/therapeutic use, Antineoplastic Agents, Alkylating/therapeutic use, Carcinoma, Basal Cell/epidemiology, Dacarbazine/therapeutic use, Drug Therapy, Combination, Humans, Immunologic Factors/therapeutic use, Ipilimumab, Melanoma/drug therapy, Psoriasis/drug therapy, Recombinant Fusion Proteins/therapeutic use, Skin Neoplasms/drug therapy, Skin Neoplasms/epidemiology
Relation: European Journal of Dermatology; https://iris.unil.ch/handle/iris/69020; serval:BIB_0A9687A755E3; 000297017400065
-
12
Autoren:
Schlagwörter: Aged, 80 and over, Angiogenesis Inhibitors/therapeutic use, Choroidal Neovascularization/drug therapy, Female, Humans, Intravitreal Injections, Male, Middle Aged, Ranibizumab/therapeutic use, Receptors, Vascular Endothelial Growth Factor/therapeutic use, Recombinant Fusion Proteins/therapeutic use, Regression Analysis, Retinal Detachment/drug therapy, Retinal Detachment/physiopathology, Retinal Pigment Epithelium/pathology, Retrospective Studies, Vascular Endothelial Growth Factor A, Visual Acuity/physiology, Wet Macular Degeneration/drug therapy, Wet Macular Degeneration/physiopathology
Relation: RETINA: The Journal of Retinal and Vitreous Diseases; https://iris.unil.ch/handle/iris/240379; serval:BIB_F36B42AA95E7; 000440623400016
-
13
Autoren: et al.
Schlagwörter: Animals, CD8-Positive T-Lymphocytes/immunology, Cancer Vaccines/immunology, Cancer Vaccines/therapeutic use, Cross-Priming, Dendritic Cells/immunology, HEK293 Cells, Humans, Killer Cells, Natural/immunology, Mice, Inbred C57BL, Neoplasms/immunology, Neoplasms/therapy, Recombinant Fusion Proteins/immunology, Recombinant Fusion Proteins/therapeutic use, CD1d, CD8+ T cell, Cross-presenting DC, Recombinant fusion protein, Tumor vaccine, Xcl1, Xcr1+ DC, iNKT cell
Relation: Methods in enzymology; https://iris.unil.ch/handle/iris/199156; serval:BIB_67289CA04690; 000556278200027
-
14
Autoren: et al.
Schlagwörter: Humans, Dexamethasone/administration & dosage, Dexamethasone/therapeutic use, Retrospective Studies, Male, Intravitreal Injections, Female, Aged, 80 and over, Vascular Endothelial Growth Factor A/antagonists & inhibitors, Ranibizumab/administration & dosage, Ranibizumab/therapeutic use, Angiogenesis Inhibitors/administration & dosage, Angiogenesis Inhibitors/therapeutic use, Visual Acuity/drug effects, Macular Degeneration/drug therapy, Receptors, Vascular Endothelial Growth Factor/administration & dosage, Vascular Endothelial Growth Factor/therapeutic use, Drug Implants, Recombinant Fusion Proteins/administration & dosage, Recombinant Fusion Proteins/therapeutic use, Glucocorticoids/administration & dosage, Glucocorticoids/therapeutic use, Wet Macular Degeneration/drug therapy, Longitudinal Studies, Ozurdex, burden of treatment, dexamethasone implant, disease stability
Relation: Journal of Ocular Pharmacology and Therapeutics; https://iris.unil.ch/handle/iris/184701; serval:BIB_B612DB5BAB1F; 001150707300001
-
15
Autoren: et al.
Schlagwörter: Adult, Antibodies, Monoclonal/therapeutic use, Antilymphocyte Serum/therapeutic use, B-Lymphocytes/immunology, Female, Heart Transplantation, Hemagglutination Inhibition Tests, Humans, Immunity, Cellular, Humoral, Immunologic Memory, Immunosuppressive Agents/therapeutic use, Influenza A Virus, H1N1 Subtype, H3N2 Subtype, Influenza Vaccines/therapeutic use, Influenza, Human/prevention & control, Kidney Transplantation, Male, Middle Aged, Prospective Studies, Recombinant Fusion Proteins/therapeutic use, T-Lymphocytes/immunology, Transplant Recipients, Biological agents, Immunogenicity, Induction
Relation: Vaccine; https://iris.unil.ch/handle/iris/119624; serval:BIB_131AECC2C5F7; 000378955600004
-
16
Autoren:
Schlagwörter: Amino Acid Sequence, Animals, Ectodermal Dysplasia/drug therapy, Female, Membrane Proteins/therapeutic use, Mice, Molecular Sequence Data, Pregnancy, Recombinant Fusion Proteins/therapeutic use
Dateibeschreibung: application/pdf
Relation: Nature Medicine; https://iris.unil.ch/handle/iris/230378; serval:BIB_DAB001E64D04; 000182610600044
-
17
Autoren: et al.
Schlagwörter: Animals, CD8-Positive T-Lymphocytes/immunology, CD8-Positive T-Lymphocytes/metabolism, Mice, Interleukin-4/metabolism, Interleukin-4/immunology, Female, TOR Serine-Threonine Kinases/metabolism, TOR Serine-Threonine Kinases/antagonists & inhibitors, Humans, Neoplasms/immunology, Neoplasms/therapy, STAT6 Transcription Factor/metabolism, Cell Line, Tumor, Immunoglobulin Fc Fragments/immunology, Recombinant Fusion Proteins/metabolism, Recombinant Fusion Proteins/therapeutic use, Male, Immune Checkpoint Inhibitors/pharmacology, Immune Checkpoint Inhibitors/therapeutic use, Inbred C57BL, Glycolysis/drug effects, Xenograft Model Antitumor Assays, Signal Transduction, Immunotherapy, Adoptive
Dateibeschreibung: application/pdf
Relation: Nature; https://iris.unil.ch/handle/iris/207491; serval:BIB_8B9B2D07B620; 001337936900027
-
18
Autoren: et al.
Weitere Verfasser: et al.
Quelle: The Lancet. 394:131-138
Schlagwörter: Male, Glucagon-Like Peptides/therapeutic use, Recombinant Fusion Proteins, Albuminuria/prevention & control, Glucagon-Like Peptides, Immunoglobulin Fc Fragments/therapeutic use, Glomerular Filtration Rate/drug effects, 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Double-Blind Method, Creatinine/urine, Diabetes Mellitus, Albuminuria, Humans, Hypoglycemic Agents, Diabetic Nephropathies/prevention & control, Diabetic Nephropathies, name=General Medicine, Aged, Type 2/drug therapy, Middle Aged, 16. Peace & justice, Immunoglobulin Fc Fragments, 3. Good health, Diabetes Mellitus, Type 2, Creatinine, Recombinant Fusion Proteins/therapeutic use, Glucagon-Like Peptides/analogs & derivatives, Female, Hypoglycemic Agents/therapeutic use, Glomerular Filtration Rate
Dateibeschreibung: 8 p; application/pdf
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/31189509
https://researchonline.gcu.ac.uk/en/publications/2be56b12-ae21-48a8-9579-b8147c232e4d
https://doi.org/10.1016/S0140-6736(19)31150-X
https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(19)31150-X.pdf
https://europepmc.org/article/MED/31189509
https://yonsei.pure.elsevier.com/en/publications/dulaglutide-and-renal-outcomes-in-type-2-diabetes-an-exploratory-
https://pure.ewha.ac.kr/en/publications/dulaglutide-and-renal-outcomes-in-type-2-diabetes-an-exploratory-
https://miami.pure.elsevier.com/en/publications/dulaglutide-and-renal-outcomes-in-type-2-diabetes-an-exploratory-
https://experts.umn.edu/en/publications/dulaglutide-and-renal-outcomes-in-type-2-diabetes-an-exploratory-
https://repositorio.udes.edu.co/handle/001/5693 -
19
Autoren: et al.
Weitere Verfasser: et al.
Quelle: The Lancet. 394:121-130
Schlagwörter: Male, Glucagon-Like Peptides/therapeutic use, Recombinant Fusion Proteins, Glucagon-Like Peptides, Myocardial Infarction, Immunoglobulin Fc Fragments/therapeutic use, SDG 3 - Good Health and Well-being, Double-Blind Method, Diabetes Mellitus, Humans, Hypoglycemic Agents, name=General Medicine, Cardiovascular Diseases/mortality, Stroke/prevention & control, Aged, Type 2/drug therapy, General Medicine, Cardiovascular Diseases/prevention & control, Middle Aged, 16. Peace & justice, Type 2/complications, Immunoglobulin Fc Fragments, 3. Good health, Stroke, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Myocardial Infarction/prevention & control, Recombinant Fusion Proteins/therapeutic use, Glucagon-Like Peptides/analogs & derivatives, Female, Hypoglycemic Agents/therapeutic use
Dateibeschreibung: 10 p; application/pdf
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/31189511
https://researchonline.gcu.ac.uk/en/publications/4c5af28a-edef-4386-8d3c-21c95edb7c0c
https://doi.org/10.1016/S0140-6736(19)31149-3
https://pure.ewha.ac.kr/en/publications/dulaglutide-and-cardiovascular-outcomes-in-type-2-diabetes-rewind
https://repositorio.udes.edu.co/handle/001/5694
https://www.sciencedirect.com/science/article/pii/S0140673619311493
https://ir.ymlib.yonsei.ac.kr/handle/22282913/174490
https://discovery.dundee.ac.uk/en/publications/dulaglutide-and-cardiovascular-outcomes-in-type-2-diabetes-rewind
https://findanexpert.unimelb.edu.au/scholarlywork/1403380-dulaglutide-and-cardiovascular-outcomes-in-type-2-diabetes-(rewind)--a-double-blind--randomised-placebo-controlled-trial.
https://repositorio.udes.edu.co/handle/001/5694 -
20
Autoren: et al.
Quelle: Acta Ophthalmol
Hartmund Frederiksen, K, Pindbo Vestergaard, J, Pedersen, F N, Stage Vergmann, A, Lykke Sørensen, T, Schmidt Laugesen, C, Kawasaki, R, Peto, T & Grauslund, J 2022, 'Navigated laser and aflibercept versus aflibercept monotherapy in treatment-naïve branch retinal vein occlusion: a 12 months randomized trial', Acta Ophthalmologica. https://doi.org/10.1111/aos.15182
Frederiksen, K H, Vestergaard, J P, Pedersen, F N, Vergmann, A S, Sørensen, T L, Laugesen, C S, Kawasaki, R, Peto, T & Grauslund, J 2022, ' Navigated laser and aflibercept versus aflibercept monotherapy in treatment-naïve branch retinal vein occlusion : A 12-month randomized trial ', Acta Ophthalmologica, vol. 100, no. 7, pp. e1503-e1509 . https://doi.org/10.1111/aos.15182Schlagwörter: Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor, Lasers, Recombinant Fusion Proteins, Visual Acuity, Angiogenesis Inhibitors, Original Articles, Recombinant Fusion Proteins/therapeutic use, Macular Edema, 3. Good health, Macular Edema/diagnosis, 03 medical and health sciences, Receptors, Vascular Endothelial Growth Factor, Treatment Outcome, 0302 clinical medicine, Retinal Vein Occlusion/diagnosis, Receptors, Intravitreal Injections, Retinal Vein Occlusion, Humans, Aged
Dateibeschreibung: application/pdf
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/35611568
https://pure.qub.ac.uk/en/publications/a9b675e6-a97c-4aa9-80d1-7aed2d606e0d
https://curis.ku.dk/ws/files/337987919/Acta_Ophthalmologica_2022_Frederiksen_Navigated_laser_and_aflibercept_versus_aflibercept_monotherapy_in_treatment_na.pdf
https://portal.findresearcher.sdu.dk/da/publications/d81da602-320f-4848-835b-4508c67153e9
https://doi.org/10.1111/aos.15182
Full Text Finder 
Nájsť tento článok vo Web of Science 
Full Text